PT - JOURNAL ARTICLE AU - P. Barmpounakis AU - N. Demiris AU - I. Kontoyiannis AU - G. Pavlakis AU - V. Sypsa TI - Evaluating the effects of vaccine rollout policies in European countries: A simulation study AID - 10.1101/2021.05.19.21257486 DP - 2021 Jan 01 TA - medRxiv PG - 2021.05.19.21257486 4099 - http://medrxiv.org/content/early/2021/05/21/2021.05.19.21257486.short 4100 - http://medrxiv.org/content/early/2021/05/21/2021.05.19.21257486.full AB - The results of a simulation-based evaluation of several policies for vaccine rollout are reported. In the presence of limited vaccine supply, this policy choice is a pressing issue for several countries worldwide, and the adopted course of action will affect the extension or easing of non-pharmaceutical interventions in the next months. We employ a suitably generalised, age-structure, stochastic SEIR (Susceptible → Exposed → Infectious → Removed) epidemic model that can accommodate quantitative descriptions of the major effects resulting from distinct vaccination strategies. The different rates of social contacts among distinct age-groups are informed by a recent survey conducted in Greece. The results are summarised and evaluated in terms of the total number of deaths and infections as well as life years lost. The optimal strategy is found to be one based on fully vaccinating the elderly/at risk as quickly as possible, while extending the time-interval between the two vaccine doses to 12 weeks for all individuals below 75 years old, in agreement with epidemic theory which suggests targeting a combination of susceptibility and infectivity. This policy, which is similar to the approaches adopted in the UK and in Canada, is found to be effective in reducing deaths and life years lost in the period while vaccination is still being carried out.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNon applicableAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Non applicableAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data and code for this project is available at https://github.com/pbarmpounakis/Evaluating-the-effects-of-vaccine-rollout-policies-in-European-countries-A-simulation-study https://github.com/pbarmpounakis/Evaluating-the-effects-of-vaccine-rollout-policies-in-European-countries-A-simulation-study